5-Amino-1MQ: the enzyme inhibitor that thinks it's exercise.

Most metabolic drugs work by adding something — a hormone, an agonist, a substrate. 5-Amino-1MQ is interesting because it works by subtraction. It sits in the active site of an enzyme called nicotinamide N-methyltransferase, blocks the methyl group from being transferred, and lets the cell hold on to two molecules it ordinarily would have lost. Those two molecules — nicotinamide and S-adenosyl-methionine — happen to be the precursors of NAD+ and the donors of every methyl tag in the genome. Subtracting one enzymatic step rearranges, downstream, a surprising amount of biology.

What NNMT does and why it matters

NNMT is a cytosolic methyltransferase. Its reaction is unsexy: take nicotinamide (vitamin B3, also the immediate precursor to NAD+), borrow a methyl group from S-adenosyl-methionine, and produce 1-methylnicotinamide plus S-adenosyl-homocysteine. In a healthy young adipocyte, NNMT activity is modest. In obese white adipose tissue and in the liver of patients with metabolic syndrome, NNMT expression rises sharply. The cell's nicotinamide pool drains. The methyl pool drains. NAD+ falls. Histone methylation patterns shift. And SIRT1 — the deacetylase that requires NAD+ as cofactor — quiets down.

The paper that put this in the literature is from Daniel Kraus and Barbara Kahn's group at Beth Israel Deaconess and Harvard Medical School, published in Nature in 2014. They showed that knocking down NNMT in white adipose tissue and liver of obese mice protected against diet-induced obesity by raising cellular energy expenditure. The paper reframed NNMT as a metabolic target, not a housekeeping enzyme.

What the inhibitor does in mice

5-Amino-1-methylquinolinium is a small-molecule inhibitor of NNMT developed at the University of Texas Medical Branch in Galveston by Stanley Watowich and Harshini Neelakantan. The 2024 paper in Diabetes, Obesity and Metabolism characterized its effect in diet-induced obese mice. After 28 days of daily dosing, treated animals showed dose-dependent reductions in body weight gain and fat mass, improved oral glucose tolerance, lower fasting insulin, and on liver histology, attenuated hepatic steatosis with reduced macrophage infiltration.

The 2024 sarcopenia paper that surprised the field

The interesting finding from a 2024 paper in Scientific Reports — Andrea Dimet-Wiley and Christopher Fry at the University of Kentucky's Center for Muscle Biology, working with Watowich's group — was not that 5-Amino-1MQ improved muscle in aged mice. It was the magnitude. Aged sedentary mice given 5-Amino-1MQ for two months gained roughly 40 percent grip strength relative to sedentary controls. Aged mice given intensive exercise gained about 20 percent. And mice given both gained about 60 percent. The effects were additive. NNMT inhibition did not just mimic exercise; it did something exercise alone could not.

Aged mice treated with NNMTi alone gained more grip strength than aged exercising mice. Combined, they gained more than either alone. That is not what 'exercise mimetic' usually means.

Beyond fat and muscle: the European heart-failure work

In June 2025, a Dutch-Swedish collaboration between the University Medical Center Groningen and AstraZeneca's R&D site in Gothenburg published in Pharmacological Research a study testing AMO-NAM, a different NNMT inhibitor, in a heart failure with preserved ejection fraction (HFpEF) mouse model. NNMT inhibition restored global longitudinal strain, reversed peak longitudinal strain rate, reduced left ventricular hypertrophy and fibrosis, lowered macrophage infiltration in both cardiac and visceral adipose tissue, and quieted pro-inflammatory and pro-fibrotic gene expression.

An odd discovery: 1-methylnicotinamide is not just a leftover

Here is where the story gets recursive. NNMT's product, 1-methylnicotinamide (MNAM), is not metabolic dead weight. A 2022 review in Current Pharmaceutical Design, led by Hamid Reza Nejabati at Tabriz University of Medical Sciences in Iran with collaborators at Mid Sweden University and Lund, made the case that MNAM is a myokine in its own right — released from skeletal muscle during high-volume training and caloric restriction, where it promotes lipolysis, gluconeogenesis, and SIRT1 expression. The same molecule that NNMT inhibition lowers in adipose tissue may be useful in working muscle.

Often studied alongside

Adjacent research has paired 5-Amino-1MQ with NAD+ precursors — the pairing is mechanistically obvious. NNMT inhibition raises the NAD+ floor by closing one consumption pathway; direct precursor supplementation raises the ceiling. Researchers studying mitochondrial biogenesis and AMPK signaling have placed 5-Amino-1MQ in protocols alongside MOTS-c, given the convergence on mitochondrial-respiration phenotypes.

Practical considerations

5-Amino-1MQ is supplied as a small-molecule research compound, not a peptide. Solubility is acceptable in DMSO and aqueous buffers at physiological pH. The 2021 LC-MS/MS pharmacokinetic work from Texas Southern University and the University of Houston established oral bioavailability around 38 percent in rats with a terminal half-life near 7 hours. All Precursor catalog entries are sold for research use only.